10 results
The objective of the study is to provide clinical evidence proving that the Aperius* PercLID* System is safe and non-inferior to Standalone Decompressive Surgery (decompressive spinal surgery without additional instrumentation/fixation) with regards…
Demonstrate the superiority of finerenone to eplerenone in delaying time to first occurrence of the compositeendpoint, defined as cardiovascular (CV) death or hospitalization for heart failure (HF), in patients withCHF (NYHA class II-IV) and reduced…
Demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the time to first occurrence of cardiovascular mortality and morbidity in subjects with T2DM and the clinical diagnosis of DKD.
Demonstrate whether, in addition to standard of care (SoC), finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of…
The main objective of this study is investigating whether augmented reality can provoke symptoms in patients with contamination-based OCD by evaluating how this AR HMD symptom provocation compares to a traditional symptom provocation.
The main objective of this study is to investigate whether body ownership directly influnces the perception of pain in individuals with BIID. The secondary outcome examines whether or not AR is also an effective tool for ameliorating physical and…
The main objective of this study is to investigate whether perspective (i.e. first person vs. third person) directly influences the interplay between body ownership and pain perception.
The main goal of this study is to find out whether finerenone in combination with either an ACE inhibitor or an ARB can reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a drug, but contains no…
Main objective:The primary objective is to demonstrate that combination therapy using finerenone and empagliflozin is superior in reducing UACR than either empagliflozin or finerenone alone.Secondary objectives:- To further investigate the efficacy…
A study to learn more about how safe the study treatment finerenone is inlong-term use when taken with an ACE inhibitor or angiotensin receptorblocker over 18 months of use in children and young adults from 1 to 18years of age with chronic kidney…